Journals / Retina-Vitreus / 2008 / Cilt: 16 - Sayı: 3

Diabetik makula ödemi tedavisinde intravitreal triamsinolon asetonid

Intravitreal triamcinolone acetonide for the treatment of diabetic macular edema

Pages
197–202
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: IVTA injection in the treatment of refractory DME was found to be effective especially for 3 months.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Purpose: The purpose of this study is to evaluate the effectiveness and complications of intravitreal triamcinolone acetonide (IVTA) injection in the treatment of diabetic macular edema (DME).
📊
Key Findings & Data:Materials and Methods: Twenty-eight eyes of 26 DME patients who were resistant to laser photocoagulation treatment were enrolled in the study.
💡
Conclusion & Impact:Conclusion: IVTA injection in the treatment of refractory DME was found to be effective especially for 3 months.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Floresan anjiyografi · Triamsinolon asetonit · Görme keskinliği

Abstract

Purpose: The purpose of this study is to evaluate the effectiveness and complications of intravitreal triamcinolone acetonide (IVTA) injection in the treatment of diabetic macular edema (DME). Materials and Methods: Twenty-eight eyes of 26 DME patients who were resistant to laser photocoagulation treatment were enrolled in the study. Triamcinolone acetonide (TA) was injected intravitreally under topical anesthesia. The patients were evaluated at the first week, and the first, third and sixth months, in terms of visual acuity (VA), intraocular pressure (IOP), presence of TA crystals in vitreous, and regression of macular edema and hard exudates in the fundus photographs and fundus fluorescein angiography. Results: The VA of the patients were 1.31±0.44 LogMAR unit before injection and improved significantly at the first week and the first and third months while there was no difference the sixth month (1.15±0.46, 1.01±0.51, 1.01±0.50, and 1.07±0.56 LogMAR units respectively). The IOP of the patients were 14.25±3.35 mmHg before injection and increased significantly at the first week and the first and third months while there was no difference the sixth month (16.07±4.27, 16.82±3.73, 17.32±6.08, and 15.35±3.15 mmHg respectively). Regression of macular edema in fundus fluorescein angiography detected in 22 (79%), 16 (57%), and 8 (31%) eyes the first, third, and sixth months respectively. TA crystals were observed in the vitreous in 26 (93%), 11 (39%), and 2 (8%) eyes the first, third and sixth months respectively. The hard exudates were regressed in 15 of 19 eyes (79%) end of the six months. One eye exhibited cataract progression. Conclusion: IVTA injection in the treatment of refractory DME was found to be effective especially for 3 months.

Özet

Amaç: Bu çalışmada diabetik makula ödemi (DMÖ) tedavisinde intravitreal triamsinolon asetonid (İVTA) enjeksiyonunun etkinliğini ve komplikasyonlarını değerlendirmek amaçlandı. Gereç ve Yöntemler: Çalışmaya lazer fotokoagülasyon tedavisine dirençli DMÖ olan 26 hastanın 28 gözü alındı. Triamsinolon asetonid (TA) topikal anestezi altında intravitreal olarak enjekte edildi. Olgular birinci hafta, birinci, üçüncü ve altıncı ayda görme keskinliği, göz içi basıncı (GİB), vitreusta TA kristallerinin varlığı ve fundus fotografları ile fundus flöresein anjiografide makula ödemi ile sert eksudaların gerilemesi açısından değerlendirildi. Bulgular: Hastaların enjeksiyon öncesi görme keskinliği 1.31±0.44 LogMAR unite olup birinci hafta, birinci ve üçüncü ayda anlamlı olarak artarken altıncı ayda anlamlı farklılık yoktu (1.15±0.46, 1.01±0.51, 1.01±0.50, 1.07±0.56 LogMAR ünite). Hastaların enjeksiyon öncesi GİB’i 14.25±3.35 mmHg olup birinci hafta, birinci ve üçüncü ayda anlamlı olarak artarken altıncı ayda anlamlı farklılık yoktu (16.07±4.27, 16.82±3.73, 17.32±6.08, 15.35±3.15 mmHg). Fundus flöresein anjiografide birinci, üçüncü ve altıncı ayda sırasıyla 22 (%79), 16 (%57) ve 8 (%31) gözde makula ödeminde gerileme saptandı. Birinci, üçüncü ve altıncı ayda sırasıyla 26 (%93), 11 (%39) ve 2 (%8) gözde vitreusta TA kristalleri izlendi. Enjeksiyon öncesi sert eksuda olan 19 gözün, altı ay sonunda 15’inde (%79) sert eksudaların gerilediği görüldü. Bir gözde katarakt ilerlemesi görüldü. Sonuç: Lazer fotokoagülasyonuna dirençli DMÖ tedavisinde İVTA enjeksiyonunun özellikle ilk 3 ay için etkili olduğu bulunmuştur.

🔖

Cite This Article

ÖZCURA, F., DÜNDAR, S., KIR, E., AYDIN, S., AKTUNÇ, T. (2008). Diabetik makula ödemi tedavisinde intravitreal triamsinolon asetonid. Retina-Vitreus, Cilt: 16 - Sayı: 3, 197–202. https://ajindex.com/articles/305187

References (15)

  1. Klein R, Klein BE, Moss SE: Visual impairment in diabetes. Ophthalmology. 1984;91:1-9
  2. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol. 1985;103:1796-1806
  3. Early Treatment Diabetic Retinopathy Study Research Group: Photocoagulation for diabetic macular edema: Early Treatment Diabetic Retinopathy Study report number 4. Int Ophthalmol Clin. 1987;27:265-272
  4. Bandello F, Pognuz R, Polito A, et al.: Diabetic macular edema: classification,medical and laser therapy. Semin Ophthalmol. 2003;18:251-258
  5. Suckling RD, Maslin KF.: Pseudophakic cystoid macular oedema and its treatment with local steroids. Aust N Z J Ophthalmol. 1988;16:353-359
  6. Machemer R, Sugita G, Tano Y.: Treatment of intraocular proliferations with intravitreal steroids. Trans Am Ophthalmol Soc. 1979;77:171-180
  7. Munir WM, Pulido JS, Sharma MC, et al.: Intravitreal triamcinolone for treatment of complicated proliferative diabetic retinopathy and proliferative vitreoretinopathy. Can J Ophthalmol. 2005; 40:598-604
  8. Antoszyk AN, Gottlieb JL, Machemer R, et al.: The effects of intravitreal triamcinolone acetonide on experimental pre-retinal neovascularization. Graefes Arch Clin Exp Ophthalmol. 1993; 231:34-40
  9. Jonas JB, Kreissig I, Hugger P, et al.: Intravitreal triamcinolone acetonide for exudative age related macular degeneration. Br J Ophthalmol. 2003;87:462-468
  10. Ip MS, Kumar KS.: Intravitreous triamcinolone acetonide as treatment for macular edema from central retinal vein occlusion. Arch Ophthalmol. 2002;120:1217-1219
  11. Chen SD, Lochhead J, Patel CK, et al.: Intravitreal triamcinolone acetonide for ischaemic macular oedema caused by branch retinal vein occlusion. Br J Ophthalmol. 2004;88:154-155
  12. Jonas JB, Kreissig I, Degenring RF.: Intravitreal triamcinolone acetonide for pseudophakic cystoid macular edema. Am J Ophthalmol. 2003;136:384-386
  13. Jonas JB, Sofker A.: Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol. 2001;132:425-427
  14. Degenring RF, Jonas JB.: Intravitreal injection of triamcinolone acetonide as treatment for chronic uveitis. Br J Ophthalmol. 2003; 87:361
  15. Jonas JB, Sofker A, Degenring R.: Intravitreal triamcinolone acetonide as an additional tool in pars plana vitrectomy for proliferative diabetic retinopathy.Eur J Ophthalmol. 2003;13:468-473. 1